Payment overview · 2025
General Payments
$448.78
29 reported records · 11 companies
Healthcare provider profile · identity verified
Todd Christian Tracy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MILFORD, CT · NPI 1780769919
Verified facts
What the public records show
CMS Open Payments records show Todd Christian Tracy, MD received $448.78 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 31.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $140.78 | 31.4% | 14 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $60.79 | 13.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.35 | 12.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.04 | 9.6% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $32.90 | 7.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.12 | 6.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.83 | 5.5% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $20.84 | 4.6% | 1 | 2025 |
| Lucid Diagnostics Inc. | Unresolved — no canonical attribution shown | $15.95 | 3.5% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $14.29 | 3.2% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $7.89 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $448.78 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $72.84 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $72.84 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $67.94 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $38.62 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $32.90 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.12 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.64 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.90 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $7.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
87 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
170 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 481 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 431 | 126 |
| Lisinopril | Lisinopril | 345 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 78 |
| Irbesartan | Irbesartan | 175 | 45 |
| Ozempic | Semaglutide | 170 | 25 |
| Metformin Hcl Er | Metformin Hcl | 168 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 43 |
| Simvastatin | Simvastatin | 159 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 40 |
| Allopurinol | Allopurinol | 133 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 36 |
| Alprazolam | Alprazolam | 120 | 40 |
| Lorazepam | Lorazepam | 109 | 27 |
| Losartan Potassium | Losartan Potassium | 106 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 93 | 24 |
| Synthroid | Levothyroxine Sodium | 87 | 22 |
| Metformin Hcl | Metformin Hcl | 83 | 23 |
| Omeprazole | Omeprazole | 79 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 24 |
| Glipizide Er | Glipizide | 72 | 20 |
| Valsartan | Valsartan | 71 | 15 |
| Ezetimibe | Ezetimibe | 69 | 19 |
| Sertraline Hcl | Sertraline Hcl | 66 | 16 |
| Carvedilol | Carvedilol | 51 | 12 |
| Furosemide | Furosemide | 50 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 50 | 19 |
| Montelukast Sodium | Montelukast Sodium | 48 | 15 |
| Meloxicam | Meloxicam | 46 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 12 |
| Eliquis | Apixaban | 45 | 11 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 26 |
| Atenolol | Atenolol | 43 | 11 |
| Famotidine | Famotidine | 43 | 12 |
| Gabapentin | Gabapentin | 43 | 13 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Jardiance | Empagliflozin | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | 11 |
| Spironolactone | Spironolactone | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | 11 |
| Dutasteride | Dutasteride | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 23 |
| Nystatin | Nystatin | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Azelastine Hcl | Azelastine Hcl | 17 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Telmisartan | Telmisartan | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $448.78 · 29 records | ABBVIE INC. | AIRSUPRA, AREXVY, Cologuard Collection Kit, FARXIGA, Fibroscan, GLYCATE, INSPIRE, Korlym, LOREEV XR, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error